- Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension, and diuresis are absent in N/OFQ peptide (NOP) receptor knockout mice
[作者:Burmeister, MA; Ansonoff, MA; Pintar, JE; Kapusta, DR,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:897-904 , 文章类型: Article,,卷期:2008年326-3]
Intracerebroventricular administration of the opioid-like peptide nociceptin/orphanin FQ (N/OFQ) produces bradycardia, hypotension, and diuresis in mice. We hypothesized that these responses are solely caused by selec...
- Olanzapine (LY170053, 2-Methyl-4-(4-methyl-1-piperazinyl)10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia, and metabolic dysregulation in mice
[作者:Coccurello, R; Caprioli, A; Conti, R; Ghirardi, O; Borsini, F; Carminati, P; Moles, A,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:905-911 , 文章类型: Article,,卷期:2008年326-3]
A mouse model of atypical antipsychotic- associated adverse effects was used to compare the liability to induce weight gain, food intake, and metabolic alterations after chronic olanzapine (OL; LY170053, 2- methyl- 4-...
- Modulation of sarcoplasmic reticulum function by PST2744 [Istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride] in a pressure-overload heart failure model
[作者:Rocchetti, M; Alemanni, M; Mostacciuolo, G; Barassi, P; Altomare, C; Chisci, R; Micheletti, R; Ferrari, P; Zaza, A,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:957-965 , 文章类型: Article,,卷期:2008年326-3]
PST2744 [Istaroxime; (E, Z)-3-((2-aminoethoxy)imino) androstane-6,17- dione hydrochloride)] is a novel inotropic agent that enhances sarco(endo) plasmic reticulum Ca2+ ATPase (SERCA) 2 activity. We investigated the is...
- Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4(trifluoromethyl) phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats (vol 326, pg 218, 2008)
[作者:Lehto, SG; Tamir, R; Deng, H; Klionsky, L; Kuang, R; Le, A; Lee, D; Louis, JC; Magal, E; Manning, BH; Rubino, R; Surapaneni, S; Tamayo, N; Wang, T; Wang, J; Wang, J; Wang, W; Youngblood, B; Zhang, M; Zhu, D; Norman, MH; Gavva, NR,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:999-999 , 文章类型: Correction,,卷期:2008年326-3]
- Licofelone suppresses prostaglandin E-2 formation by interference with the inducible microsomal prostaglandin E-2 synthase-1
[作者:Koeberle, A; Siemoneit, U; Hring, UB; Northoff, H; Laufer, S; Albrecht, W; Werz, O,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:975-982 , 文章类型: Article,,卷期:2008年326-3]
The anti-inflammatory drug licofelone [=ML3000; 2-[ 6-(4-chlorophenyl)2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid], currently undergoing phase III trials for osteoarthritis, inhibits the prostagl...
- Circadian variations in rat liver gene expression: Relationships to drug actions
[作者:Almon, RR; Yang, E; Lai, W; Androulakis, IP; DuBois, DC; Jusko, WJ,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:700-716 , 文章类型: Article,,卷期:2008年326-3]
Chronopharmacology is an important but under-explored aspect of therapeutics. Rhythmic variations in biological processes can influence drug action, including pharmacodynamic responses, due to circadian variations in ...
- Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals
[作者:Hawkins, JL; Robbins, MD; Warren, LC; Xia, DH; Petras, SF; Valentine, JJ; Varghese, AH; Wang, IK; Subashi, TA; Shelly, LD; Hay, BA; Landschulz, KT; Geoghegan, KF; Harwood, HJ,期刊:Journal of Pharmacology and Experimental Therapeutics, 页码:801-808 , 文章类型: Article,,卷期:2008年326-3]
Sterol regulatory element-binding proteins (SREBPs) are major transcriptional regulators of cholesterol, fatty acid, and glucose metabolism. Genetic disruption of SREBP activity reduces plasma and liver levels of chol...
|